Mereo BioPharma Group Plc develops therapeutics for oncology and rare diseases, focusing on setrusumab for osteogenesis imperfecta and alvelestat for alpha-1-antitrypsin deficiency. The company also has oncology candidates and partnered programs like Navicixizumab.
Mereo Biopharma Group Plc (MREO) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Mereo Biopharma Group Plc's actual EPS was -$0.04, missing the estimate of -$0.01 per share, resulting in a -222.56% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
